Abstract
Background: The fixed combination of extrafine beclometasone dipropionate 100 μg/formoterol 6 μg (extrafine BDP/F) delivered by NEXThaler has proved to be effective in patients with moderate-to-severe asthma in terms of lung function, symptoms and asthma control. The aim of this study was to investigate the usability/satisfaction of NEXThaler and adherence to treatment in asthma patients not well controlled by low-dose inhaled corticosteroids (ICS). Methods: This was a 6-month prospective, multicenter, open-label, observational study in 661 patients with asthma not well controlled by low-dose ICS according to the physician’s clinical assessment, which have received regular treatment with extrafine BDP/F NEXThaler. Feeling of Satisfaction with Inhaler (FSI), treatment adherence with self-reported Morisky scale, asthma control, lung function and QoL were recorded at baseline, 3 and 6 months after treatment with extrafine BDP/F. Results: The percentage of patients at least “fairly” satisfied with NEXThaler usability (FSI-10 score 40 to 50) was 96.3%. The mean FSI-10 total score was 46.8 ± 4.4 on Visit 2 and increased to 48.1 ± 3.3 on Visit 3 (p < 0.001). Approximately 67% of the patients reported “high adherence” on Visit 2, and 70% of them reported “high adherence” on Visit 3. The percentage of patients with ACQ-6-uncontrolled asthma decreased from 79.1% on Visit 1 to 22.3% on Visit 2 and further decreased to 6.7% on Visit 3. Significant improvements were also observed in the total AQLQ score, predicted FEV1% and reduction in rescue medication use. Conclusions: The NEXThaler device, delivering a combination of BDP/F, achieves satisfaction and high adherence in patients with asthma not well controlled with low-dose ICS. Asthma control, QoL, lung function and rescue medication use were improved in a Greek real-world setting.
Highlights
Asthma is a heterogeneous chronic inflammatory disease of the airways that represents a major global public health issue affecting all age groups
The aim of this study is to investigate the usability and satisfaction of NEXThaler delivering extrafine formulation of beclometasone dipropionate μg/formoterol μg (BDP/F) and explore adherence to treatment, in patients with asthma not well controlled by low-dose inhaled corticosteroid (ICS)
DisIcnutshseiopnresent study, we evaluated the usability and patient satisfaction of the NEXThalIenr dtheveicperedseelinvtersitnugdtyh,ewinehaelvedalucoamtebdintahteionusoafbBilDitPy/aFnedxtrpaafitnieenftorsmatuislfaatciotinonin opfa-the NtiEeXntTshwailtehr adsetvhimcea dneoltivweerlilncgonthtreoillnehdableydlocwom-dboisneaItCioSn
Summary
Asthma is a heterogeneous chronic inflammatory disease of the airways that represents a major global public health issue affecting all age groups. Due to its increasing prevalence rates and rising treatment costs, it imposes an unacceptable burden to the patients and the community [1–3] It is characterized by variable airflow obstruction, bronchial hyperresponsiveness and airway inflammation [1]. The aim of this study was to investigate the usability/satisfaction of NEXThaler and adherence to treatment in asthma patients not well controlled by low-dose inhaled corticosteroids (ICS). Methods: This was a 6-month prospective, multicenter, open-label, observational study in 661 patients with asthma not well controlled by low-dose ICS according to the physician’s clinical assessment, which have received regular treatment with extrafine BDP/F NEXThaler. Conclusions: The NEXThaler device, delivering a combination of BDP/F, achieves satisfaction and high adherence in patients with asthma not well controlled with low-dose ICS. QoL, lung function and rescue medication use were improved in a Greek real-world setting
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
